Group Introduction
[Its Dual-Listed Companies] Joincare Pharmaceutical Group (Stock Code: 600380 GDR Code：JCARE) Livzon Pharmaceutical Group (Stock Code: 000513 Hong Kong Stock Code: 01513)
Haibin Pharmaceutical Co., Ltd., Shenzhen
Shenzhen Haibin Pharmaceutical Co., Ltd. (hereinafter referred to as "Haibin Pharmaceutical") was established in 1989 and officially put into production in 1992. It is a privately owned enterprise and a wholly-owned subsidiary of Joincare Pharmaceutical Group Industry Co., Ltd., a domestic A-share listed company. Haibin Pharmaceutical is located in the national ecological and environmental protection demonstration zone of Yantian District, Shenzhen, backed by Wutong Mountain and facing Dapeng Bay; it is directly connected to Hong Kong via the Shatoujiao port, close to the world-class container port of Yantian Port, with shipping routes reaching more than 80 countries and regions. The factory covers an area of 16,000 m2 and has a building area of 26,800 m2. Haibin Pharmaceutical mainly produces antibiotics. It is one of the earliest domestic companies to research and launch carbapenem antibiotics, the first domestic company capable of independently producing meropenem raw materials and preparations, and the first company globally with a complete carbapenem antibiotic product chain. The company's business scope includes chemical raw materials and preparations, antibiotics, cardiovascular drugs, traditional Chinese medicines, etc. The key product, meropenem raw materials and preparations, is a high-end product that has passed EU-GMP certification in China.
Haibin Pharmaceutical currently has multiple GMP-compliant production lines, such as carbapenem raw materials and preparation production lines, chemical raw materials and preparation production lines, oral solid preparation production lines, freeze-dried raw material production lines, etc. Since its establishment, Haibin Pharmaceutical has always adhered to the corporate spirit of diligence, exploration, rigor, and efficiency, and the business philosophy of people-oriented. After more than ten years of efforts, it has achieved remarkable results. Combining domestic and international GMP standards, Haibin Pharmaceutical continuously improves and establishes a rigorous, scientific, and systematic quality management system that meets EU and US GMP requirements. It has testing facilities such as a sterility testing room and a microbial limit testing room, and is equipped with advanced testing instruments and equipment such as high-performance liquid chromatographs, gas chromatographs, and infrared spectrophotometers, which can fully meet the testing needs of products. Every link from production to finished product delivery requires standardization, rigor, and precision. Through years of unremitting efforts, it has successively obtained certificates such as "National High-tech Enterprise," "Shenzhen High-tech Enterprise," "Guangdong Provincial Autonomous Innovation Demonstration Enterprise," "Guangdong Provincial Intellectual Property Demonstration Enterprise," "Excellent Group Member of Guangdong Provincial Drug Quality Authorizer," and "International ISO14001, OHSAS18001 system certification".
New product research and development and process improvement are the driving force for the company's sustainable development and one of our core competitive advantages. In 1999, Shenzhen Haibin Pharmaceutical Co., Ltd. began researching a new generation of highly effective broad-spectrum antibacterial drugs—carbapenem antibiotics. The quality of meropenem raw materials and preparations has reached the standards of the United States Pharmacopeia, and it possesses multiple Chinese and international patents related to meropenem production processes. Currently, the company focuses on carbapenem antibiotics, not only has basically completed the process research of new drugs such as imipenem, faropenem, and biapenem, but also has significantly optimized and innovated the processes of raw materials and side chains of these products. As a leading product among today's antibiotics, this series of products has surprising efficacy for difficult-to-control infections. Its successful development will not only bring the company new and longer-lasting profit growth points but will also surely write a new chapter in the field of Chinese antibiotics.
As a member of the pharmaceutical industry, we have an inescapable responsibility to develop the pharmaceutical industry and safeguard human health. We believe that as long as we adhere to the goal of "sincerely dedicating ourselves to the health industry" and uphold the style of "caring, loving, rigorous, and conscientious," constantly innovating and striving hard, Haibin Pharmaceutical will surely become a shining pearl in the Chinese pharmaceutical industry.
Official website link: http://www.szhaibin.com
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.